Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies

This study traces the use of the anticancer drug capecitabine through its loss of patent protection to evaluate the effect of generic pricing on the cost of oral anticancer drugs.

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JAMA Intern Med
Prif Awduron: Cole, Ashley L., Sanoff, Hanna K., Dusetzina, Stacie B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Medical Association 2017
Pynciau:
Research Letter
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5820701/
https://ncbi.nlm.nih.gov/pubmed/28892541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2017.2788
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg